Literature DB >> 22566060

Venous thromboembolism: EINSTEIN transforms anticoagulant therapy in acute PE.

Jeffrey A Kline, Donald M Yealy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22566060     DOI： 10.1038/nrcardio.2012.65

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  10 in total

Review 1.  Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure.

Authors:  Andrea Lee; Mark Crowther
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

2.  Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association.

Authors:  Michael R Jaff; M Sean McMurtry; Stephen L Archer; Mary Cushman; Neil Goldenberg; Samuel Z Goldhaber; J Stephen Jenkins; Jeffrey A Kline; Andrew D Michaels; Patricia Thistlethwaite; Suresh Vedantham; R James White; Brenda K Zierler
Journal:  Circulation       Date:  2011-03-21       Impact factor: 29.690

Review 3.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Anne Holbrook; Sam Schulman; Daniel M Witt; Per Olav Vandvik; Jason Fish; Michael J Kovacs; Peter J Svensson; David L Veenstra; Mark Crowther; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 4.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

5.  Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.

Authors:  Meyer Michel Samama; Jean-Luc Martinoli; Léna LeFlem; Céline Guinet; Geneviève Plu-Bureau; François Depasse; Elisabeth Perzborn
Journal:  Thromb Haemost       Date:  2010-02-02       Impact factor: 5.249

6.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

Authors:  Harry R Büller; Martin H Prins; Anthonie W A Lensin; Hervé Decousus; Barry F Jacobson; Erich Minar; Jaromir Chlumsky; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Alexander Cohen; Scott D Berkowitz; Henri Bounameaux; Bruce L Davidson; Frank Misselwitz; Alex S Gallus; Gary E Raskob; Sebastian Schellong; Annelise Segers
Journal:  N Engl J Med       Date:  2012-03-26       Impact factor: 91.245

7.  Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.

Authors:  Steve Deitelzweig; Alpesh Amin; Yonghua Jing; Dinara Makenbaeva; Daniel Wiederkehr; Jay Lin; John Graham
Journal:  J Med Econ       Date:  2012-04-13       Impact factor: 2.448

8.  Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.

Authors:  Meyer Michel Samama; Genevieve Contant; Theodore E Spiro; Elisabeth Perzborn; Céline Guinet; Yves Gourmelin; Léna Le Flem; Gabriele Rohde; Jean Luc Martinoli
Journal:  Thromb Haemost       Date:  2011-12-21       Impact factor: 5.249

9.  Risk stratification for acute pulmonary embolism.

Authors:  Jeffrey A Kline; David W Miller
Journal:  J Natl Compr Canc Netw       Date:  2011-07-01       Impact factor: 11.908

Review 10.  Resolution of thromboemboli in patients with acute pulmonary embolism: a systematic review.

Authors:  Mathilde Nijkeuter; Marcel M C Hovens; Bruce L Davidson; Menno V Huisman
Journal:  Chest       Date:  2006-01       Impact factor: 9.410
  10 in total
  1 in total

1.  Immediate Discharge and Home Treatment With Rivaroxaban of Low-risk Venous Thromboembolism Diagnosed in Two U.S. Emergency Departments: A One-year Preplanned Analysis.

Authors:  Daren M Beam; Zachary P Kahler; Jeffrey A Kline
Journal:  Acad Emerg Med       Date:  2015-06-25       Impact factor: 3.451
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.